Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tredaptive launched in UK

This article was originally published in Scrip

Executive Summary

Merck Sharp & Dohme (Merck & Co) has launched its dyslipidaemia treatment Tredaptive (nicotinic acid 1,000mg plus laropiprant 20mg) tablets in the UK. The product is indicated for patients with combined mixed dyslipidaemia or primary hypercholesterolaemia. It should be used in combination with a statin when statin monotherapy is inadequate in lowering cholesterol, or as monotherapy in patients intolerant of statins or for whom statin therapy is inappropriate. It costs £16.73 for 28 tablets and £33.46 for 56 tablets. The European Commission approved a centralised marketing authorisation for Tredaptive in July last year. It is already launched in Ireland.

You may also be interested in...

Generic Topamax launched in European markets

Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.

Cervarix link to UK girl's death "unlikely"

Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.

NICE confirms limits on Alimta for lung cancer

Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts